Published in J Pharmacol Exp Ther on November 10, 2006
Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol (2008) 1.49
Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol (2014) 0.90
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol (2010) 0.85
Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J Med Chem (2011) 0.85
Evidence for Integrin - Venus Kinase Receptor 1 Alliance in the Ovary of Schistosoma mansoni Females Controlling Cell Survival. PLoS Pathog (2017) 0.75
MICA Expression Is Regulated by Cell Adhesion and Contact in a FAK/Src-Dependent Manner. Front Immunol (2017) 0.75
Endothelial cell migration during angiogenesis. Circ Res (2007) 4.67
EVENDOL, a new behavioral pain scale for children ages 0 to 7 years in the emergency department: design and validation. Pain (2012) 3.92
IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol (2010) 1.65
Continuous peripheral nerve blocks at home for treatment of recurrent complex regional pain syndrome I in children. Anesthesiology (2005) 1.64
Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene (2004) 1.64
Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem (2004) 1.50
Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron (2008) 1.37
Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem (2006) 1.36
Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis (2007) 1.29
Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones (2003) 1.29
Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res (2008) 1.19
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell (2007) 1.18
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des (2003) 1.14
Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res (2006) 1.07
Molecular cloning of the human platelet-derived growth factor receptor beta (PDGFR-beta) promoter and drug targeting of the G-quadruplex-forming region to repress PDGFR-beta expression. Biochemistry (2010) 1.06
DAP kinase mediates the phosphorylation of tropomyosin-1 downstream of the ERK pathway, which regulates the formation of stress fibers in response to oxidative stress. J Cell Sci (2007) 1.06
Extracellular signal-regulated kinase mediates phosphorylation of tropomyosin-1 to promote cytoskeleton remodeling in response to oxidative stress: impact on membrane blebbing. Mol Biol Cell (2003) 1.05
UVB-mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53. Biochem J (2002) 1.00
Annexin-1-mediated endothelial cell migration and angiogenesis are regulated by vascular endothelial growth factor (VEGF)-induced inhibition of miR-196a expression. J Biol Chem (2012) 0.99
Regulation of vascular endothelial growth factor-induced endothelial cell migration by LIM kinase 1-mediated phosphorylation of annexin 1. J Biol Chem (2010) 0.96
Adhesion of HT-29 colon carcinoma cells to endothelial cells requires sequential events involving E-selectin and integrin beta4. Clin Exp Metastasis (2004) 0.96
Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires Notch signaling. Proc Natl Acad Sci U S A (2012) 0.95
MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis (2005) 0.94
Perioperative continuous peripheral nerve blocks with disposable infusion pumps in children: a prospective descriptive study. Anesth Analg (2003) 0.94
Massive cell vacuolization induced by organic amines such as procainamide. J Pharmacol Exp Ther (2004) 0.93
A preexisting microvascular network benefits in vivo revascularization of a microvascularized tissue-engineered skin substitute. Tissue Eng Part A (2010) 0.92
Kinin receptors: functional aspects. Int Immunopharmacol (2002) 0.92
Survival advantages conferred to colon cancer cells by E-selectin-induced activation of the PI3K-NFκB survival axis downstream of Death receptor-3. BMC Cancer (2011) 0.91
Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation. Mol Cell Biol (2013) 0.91
Dysregulation of the endothelial cellular response to oxidative stress in cancer. Mol Carcinog (2006) 0.91
Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging (2010) 0.91
Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res (2004) 0.88
Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann N Y Acad Sci (2002) 0.87
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration. Breast Cancer Res (2012) 0.87
Covalent grafting of fibronectin onto plasma-treated PTFE: influence of the conjugation strategy on fibronectin biological activity. Macromol Biosci (2007) 0.86
Vascular smooth muscle contractility assays for inflammatory and immunological mediators. Int Immunopharmacol (2010) 0.85
On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascul Pharmacol (2009) 0.85
Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J Med Chem (2011) 0.85
Glutathione peroxidase-1 expression enhances recovery of human breast carcinoma cells from hyperoxic cell cycle arrest. Free Radic Biol Med (2002) 0.84
miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF. Angiogenesis (2012) 0.84
Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int J Oncol (2005) 0.83
A facile synthesis of C(2)-symmetric 17 beta-estradiol dimers. Bioorg Med Chem Lett (2003) 0.83
Women's decision making about the use of natural health products at menopause: a needs assessment and patient decision aid. J Altern Complement Med (2007) 0.83
N-Phenyl-N'-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin. Bioorg Med Chem (2006) 0.82
Engineering surfaces for bioconjugation: developing strategies and quantifying the extent of the reactions. Bioconjug Chem (2004) 0.82
Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity. Bioorg Med Chem (2005) 0.81
New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia. Cancer Res (2007) 0.81
Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors. Br J Pharmacol (2009) 0.81
Regulation of endothelial permeability and transendothelial migration of cancer cells by tropomyosin-1 phosphorylation. Vasc Cell (2012) 0.80
[Standards, options and recommendations for the management of procedure-related pain (lumbar puncture, bone marrow aspiration or biopsy, blood sampling) in children patients with cancer (summary report)]. Bull Cancer (2006) 0.80
N-Phenyl-N'-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: role of carbonyl groups in the covalent binding to the colchicine-binding site. Bioorg Med Chem (2007) 0.79
Recent advances in colorectal cancer research: the microenvironment impact. Cancer Microenviron (2011) 0.79
ASK1-P38 pathway is important for anoikis induced by microtubule-targeting aryl chloroethylureas. J Pharm Pharm Sci (2010) 0.79
Notch-dependent regulation of the ischemic vasodilatory response--brief report. Arterioscler Thromb Vasc Biol (2013) 0.79
N-substituted 4-aminobenzamides (procainamide analogs): an assessment of multiple cellular effects concerning ion trapping. Mol Pharmacol (2005) 0.79
Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships. Eur J Med Chem (2011) 0.79
Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg Med Chem (2007) 0.79
Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site. Biol Proced Online (2010) 0.78
Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation. Bioorg Med Chem Lett (2008) 0.78
N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety? Bioorg Med Chem Lett (2007) 0.78
Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas. Eur J Med Chem (2010) 0.78
Development of a tridimensional microvascularized human skin substitute to study melanoma biology. Clin Exp Metastasis (2012) 0.78
Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells. Int J Cancer (2004) 0.78
Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression. Bioorg Med Chem (2008) 0.78
Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents. Bioorg Med Chem (2008) 0.78
Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. Bioorg Med Chem (2009) 0.78
Recent advances in stress signaling in cancer. Cancer Res (2004) 0.77
Spectroscopic characterization of DMPC/DOTAP cationic liposomes and their interactions with DNA and drugs. Chem Phys Lipids (2009) 0.77